Moderna stock price forecast historical rebound data shows average

Historical rebound data shows average recovery of 9% within 30 trading days post similar declines, positioning upside toward $ Analyst price target for MRNA is US$140 which is 7.6% below our fair value estimate However, the stock has made single-digit gains in the last month, which could suggest investors are seeing a bottom. Other data points suggest that any bullish news could send Moderna stock much higher. The latest Moderna stock price forecast sees upside if positive phase-3 trial results are confirmed this quarter. Current RSI near 56 shows neutral momentum, while earnings guidance could push the price toward $110 if revenue rebounds in the seasonal vaccine cycle.